Specialised Services clinical commissioning policies and service specification - 4th Wave

Overview

NHS England has today (22 February 2016) launched a 30 day public consultation on a proposed number of new products for specialised services, (including service specifications and clinical commissioning policies). There has already been extensive engagement on these national specifications and policies, as they have been developed with the support and input of lead clinicans and patient and public representatives. This approach has helped ensure that the views of key stakeholders have informed and influenced the development of the specifications and policies to date. Please note this is one of several public consultations on a proposed number of new draft products for specialised services. We now wish to test them further with wider groups of stakeholders.

Related documents

Service Specification

Specialised Respiratory Services (adult) – Severe Asthma

• Draft Severe Asthma Service Specification
• Engagement Report
• Impact Assessment Report

Specialised Vascular Services (Adults)

• Draft Specialised Vascular Service Specification
• Engagement Report
• Impact Assessment Report

Clinical Commissioning Policies

Pegvisomant for acromegaly as a third-line treatment (adults):

• Pegvisomant for acromegaly as a third-line treatment (adults): Clinical Commissioning Policy Proposition
• Engagement Report
• Impact Assessment Report
• Evidence Review
• Clinical Panel Report

Tolvaptan for hyponatraemia secondary to the Syndrome of Inappropriate Antidiuretic Hormone (SIADH) in patients requiring cancer chemotherapy:

• Tolvaptan for hyponatraemia secondary to the Syndrome of Inappropriate Antidiuretic Hormone (SIADH) in patients requiring cancer chemotherapy: Clinical Commissioning Policy Proposition
• Engagement Report
• Impact Assessment Report
• Evidence Review
• Clinical Panel Report

Cinacalcet for complex primary hyperparathyroidism:

• Cinacalcet for complex primary hyperparathyroidism: Clinical Commissioning Policy Proposition
• Engagement Report
• Impact Assessment Report
• Evidence Review
• Clinical Panel Report

Teriparatide for the treatment of osteogenesis imperfecta (Adults):

• Teriparatide for the treatment of osteogenesis imperfecta (Adults): Clinical Commissioning Policy Proposition
• Engagement Report
• Impact Assessment Report
• Evidence Review
• Clinical Panel Report

Pasireotide for acromegaly as third-line treatment (adults):

• Pasireotide for acromegaly as third-line treatment (adults): Clinical Commissioning Policy Proposition
• Engagement Report
• Impact Assessment Report
• Evidence Review
• Clinical Panel Report

Rituximab for immunoglobulin G4-related disease (IgG4-RD):

• Rituximab for immunoglobulin G4-related disease (IgG4-RD): Clinical Commissioning Policy Proposition
• Engagement Report
• Impact Assessment Report
• Evidence Review
• Clinical Panel Report

Immune Tolerance Induction (ITI) for haemophilia A (all ages):

• Immune Tolerance Induction (ITI) for haemophilia A (all ages): Clinical Commissioning Policy
• Engagement Report
• Impact Assessment Report
• Evidence Review
• Clinical Panel Report